Investing.com -- AIM ImmunoTech (NYSE: AIM) Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback